This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
所属
This person is not affiliated with any business or Blue Board record at ProZ.com.
英語 から スペイン語: English to Spanish Medical Translation - Example 1 Detailed field: 医療: 製薬
原書のテキスト - 英語 Keytruda Elicits Complete Response in 40% of Group of High-risk Bladder Cancer Patients, Early Phase 2 Trial Data Show
The immune checkpoint inhibitor Keytruda (pembrolizumab) completely eliminated tumors in almost 40% of a group of bladder cancer patients in an ongoing Phase 2 trial, Merck (known as MSD outside the U.S. and Canada) announced.
The interim analysis also found an additional 55% of these high-risk patients showed a reduction in tumor burden.
The open-label trial, called KEYNOTE-057, is enrolling patients with high risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) — where the disease is still confined to the bladder wall — and with or without papillary disease (cancer cells are arranged in finger-like projections).
The findings were recently presented during the European Society of Medical Oncology (ESMO) 2018 Annual Meeting, in Munich.
Keytruda is a type of therapy called an immune checkpoint inhibitor. It binds to the PD-1 protein on immune T-cells, blocking its binding to PD-L1 on tumor cells. Cancer cells use the interaction between PD-1 and PD-L1 to evade immune attack.
Treatment with Keytruda is intended to increase the immune system’s anti-cancer response.
The medicine is approved for a kind of bladder and urinary tract cancer called urothelial carcinoma, and researchers are now investigating its efficacy among NMIBC patients.
KEYNOTE-057 includes patients who failed to respond to Bacillus Calmette-Guérin (BCG) therapy, the current standard of care for NMIBC. All enrolled are being treated with pembrolizumab, 200 mg, given intravenously every three weeks for up to 24 months.
翻訳 - スペイン語 Resultados de Ensayos Clínicos de Fase II Temprana demuestran que Keytruda induce una respuesta completa en 40% de los pacientes con cáncer de vejiga de alto riesgo
El inhibidor de punto de control inmunitario Keytruda (pembrolizumab) eliminó completamente los tumores en aproximadamente 40% de los pacientes con cáncer de vejiga en un ensayo clínico de fase II actualmente en curso, anunció Merck (conocido como MSD fuera de Los Estados Unidos y Canadá).
El análisis provisional también reveló una reducción adicional de la carga tumoral en el 55% de los pacientes de alto riesgo.
El estudio abierto, llamado KEYNOTE-057, se encuentra actualmente seleccionando pacientes con carcinoma de vejiga no músculo-invasivo (CVNMI) con carcinoma in situ (CIS) - enfermedad que se encuentra aún confinada a la pared vesical - con o sin enfermedad papilar (células cancerosas organizadas en proyecciones con forma de dedos). Estos hallazgos fueron presentados recientemente en la Reunión Anual de la Sociedad Europea de Oncología Médica (ESMO) 2018, en Munich.
Keytruda pertenece a una clase de terapia denominada inhibidor de punto de control inmunitario. Es capaz de unirse a la proteína PD-1 de los linfocitos T, bloqueando así la unión con PD-L1 presente en las células tumorales. Las células cancerosas utilizan la interacción entre PD-1 y PD-L1 para evadir el sistema inmunitario.
El tratamiento con Keytruda tiene como finalidad incrementar la respuesta anti-cancerosa por parte del sistema inmunitario. El medicamento ha sido aprobado para un tipo en particular de cáncer de vejiga y del tracto urinario llamado carcinoma urotelial, y actualmente los científicos están investigando su eficacia en pacientes con CVNMI.
KEYNOTE-057 incluye pacientes que no han respondido al tratamiento con Bacillus Calmette-Guérin (BCG), el tratamiento médico estándar para CVNMI. Todos los pacientes seleccionados están siendo tratados con 200 mg de pembrolizumab, administrado por vía intravenosa cada tres semanas por un máximo de 24 meses.
PhD Scientist (US citizen) with more than eight years
of experience translating from English to Spanish (Medical,
Scientific, Pharmaceutical documents).
Expertise in the areas of Medicine, Immunology, Cancer,
Tumor Immunology, Inflammation, T-cells, Natural Compounds, Nutrition, Adhesion
Molecules, and Virology.
Source Language: English
Target Language: Spanish
Type of
Documents:
Clinical Research Documents,
Scientific Papers, Biology/Immunology textbooks, Investigator Brochures,
Patient Questionnaires, Scientific Articles (Magazines), Informed Consent Forms
(ICFs), Package and Labeling, Pharmacological Studies, Regulatory Documents,
Pharmaceuticals, Pharmacological Studies, Marketing communication texts, Kit
Package Inserts, Clinical Laboratory Reports, Laboratory Protocols, GMP and
Standard Operating Procedures (SOPs), Biotechnology documents/articles.
キーワード： Action, aging, AIDS, allergy, analysis, antibiotics, antibodies, asthma, autoimmune, bacterial. See more.Action, aging, AIDS, allergy, analysis, antibiotics, antibodies, asthma, autoimmune, bacterial, bacteriology, biology, biomedical translation, bioscience, biochemical, biochemistry, bioanalysis, biomedicine, biomedical sciences, biotechnology, blood, books, brain, brochures, cancer, catalogs, cell, cell biology, cell culture, certificates, clarity, clinical, clinical journals, clinical trials, coagulation, cholesterol, commitment, cytometry, diabetes, diagnosis, diagnostic, diploma, disease, doctor, education, ELISA, embryology, endocrinology, epidemiology, English to Spanish Translation, English to Spanish translator, environmental health, enzymes, experiments, experimental sciences, expertise, extraordinary, flow cytometry, focus, food, gastroenterology, gastrointestinal, genetically engineered mice, giemsa wright, goals, gratitude, guarantee, happiness, health, health care, health consultant, health education, health professional, health sciences, healthcare, hematology, herbal, histology, hormones, hospital, human potential, illness, immunobiology, immunochemistry, immunoessays, immunological test, immunological test procedure, immunology, immunologist, immigration, inflammation, inflammatory diseases, infectious diseases, informed consents, inserts, insulin, kidneys, lab kits, laboral health and security, laboratory, laboratory animals, laboratory kits, leukocyte, life sciences, lymphocyte, lymphocytes, liver, magister, manuals, material safety data sheet, medical, medical education, medical journals, medical handbooks, medical professionals, medical reports, translation medical reports, medical research, medical terminology, medical tests, medical and health translation, medical translation, medical translations, master, masters, Masters Degree, medicinal, medicine, metastasis, mice, microscope, microbiology, microscopic, microscopy, murine models, mycology, natural health, native Spanish translator, nature, neurosciences, neurology, neutral Spanish, North Carolina, nutrient, nutrition, nutritional information, oncology, parasitology, passion, patient, patient information, patient guide, personal development, personal health, pharmaceutical, new perspective, pharmaceutical drugs, pharmacology, pathology, physiology, physiopathology, platelets, pregnancy, presentation, prevention, preventative, preventive medicine, professional, protocols, project, projects, proz.com, public health, publications, research, results, sanitary, science, scientific journals, scientific papers, scientific research, scientist, specimen collection, stem cells, thesis, thyroid, translation, translations, translator, tuberculosis, university, university hospital, urinalysis, urine, vaccination, vaccines, vitamin, virology, virus, water, alimentos, análisis, análisis clínico, análisis de laboratorio, anemia, animales de laboratorio, bacteriología, biología, bioquímica, biotecnología, células madre, ciencia, científica, científico, citometría de flujo, clínico, coagulación, colesterol, cultivo celular, cultivos celulares, dengue, educación, embarazo, enfermedad, ensayos clínicos, enzimas, eosinofilia, fisiología, formularios de consentimiento, glóbulos rojos, hematología, hígado, histología, hormonas, informes médicos, inmunoensayo, inmunología, investigación, investigaciones científicas, laboratorio, leucocitos, malaria, médica, medicamentos, medicina, médico, medio ambiente, melanoma, micología, microbiología, microscopio, múridos, parásitos, plantas medicinales, pruebas funcionales de laboratorio, ratones, riñón, salud, salud pública, sangre, sangre y derivados, título universitario, traducción biomédica, triglicéridos, universidad, Universidad Central de Venezuela, Venezuela, vacunas, virología, vitaminas. See less.
専門知識分野